Physician profile
Danny Silver
NPI 1972582260
$7,472.24
in general payments reported to CMS, 2019-2025
41 companies · $1,025 in 2025
The $1,025 reported for 2025 was more than what 95% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $687 · 2020: $1,480 · 2021: $1,174 · 2022: $423 · 2023: $2,256 · 2024: $427 · 2025: $1,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,333 · Travel and Lodging: $1,375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,333.30 |
| Travel and Lodging | $1,374.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,991.59 | 2023 | Synchromedii, Intellis Adaptivestim |
| Medtronic USA, INC. | $1,111.69 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $992.18 | 2019-2025 | Relistor, Xifaxan, Trulance |
| Biohaven Pharmaceuticals, INC. | $428.87 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $402.52 | 2020-2025 | Belbuca, Xtampza |
| Abbvie INC. | $251.57 | 2021-2024 | Qulipta |
| Paratek Pharmaceuticals, INC. | $223.03 | 2025 | Nuzyra, Xhance |
| Avanir Pharmaceuticals, INC. | $207.38 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $202.49 | 2020-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $179.03 | 2019-2020 | |
| Pfizer INC. | $158.45 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $144.84 | 2024-2025 | Austedo Xr, Austedo Xr |
| Lilly USA, LLC | $82.77 | 2021-2024 | Taltz |
| Eisai INC. | $74.03 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $71.65 | 2019-2024 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Silver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.